Clinical Trials Browser

Phase 2 × Docetaxel × Thoracic × Clear all

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780098 2026-04-01

MK-3475-01I

Phase 2 Recruiting

Lung Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06841055 2026-03-13

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT07246863 2026-03-04

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04884282 2026-02-06

COMBI-TED

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT07306624 2026-01-15

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06029127 2026-01-05

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Phase 2 Active not recruiting

Lung Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05676931 2025-10-02

EDGE-Lung

Phase 2 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT05020457 2025-09-26

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT00334815 2025-08-24

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT04725188 2025-08-15

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Phase 2 Completed

255 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

175 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06929936 2025-06-08

PROTECT-1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01652820 2025-05-23

GECP0008

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04364620 2025-04-06

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

Phase 2 Completed

35 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05800587 2025-04-04

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05215067 2025-03-12

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced Non-small Cell Lung Cancer

NCT04880863 2025-03-03

NT-NAP-102-1

Phase 2 Completed

38 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05599789 2025-02-18

KeyPemls-004

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06775483 2025-01-15

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Phase 2 Not yet recruiting

Advanced Non-small Cell Lung Cancer

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2 Recruiting

Lung Neoplasms

NCT00686985 2024-09-20

DOCAR

Phase 2 Completed

Small Cell Lung Carcinoma

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2 Completed

166 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06421298 2024-05-20

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Phase 2 Recruiting

Lung Neoplasms

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03646968 2023-12-27

SAVE

Phase 2 Unknown

Non-Squamous Non Small Cell Lung Cancer

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03845270 2023-12-19

R2D2

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05863325 2023-11-07

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01750281 2023-10-24

SELECT-2

Phase 2 Completed

212 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03228186 2023-10-23

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00118131 2023-08-15

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

49 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms